Drug intelligence / Profile preview

RBFIX-FE

Development stage: Unknown
Lead developer: Biokindle Lifesciences
Modality: Small Molecules
Administration: Oral

Overview

RBFIX-FE is an oral hematinic and nutritional supplement developed by Biokindle Lifesciences. It is formulated as a tablet containing a combination of ferrous ascorbate (equivalent to 100 mg of elemental iron) and a comprehensive B-vitamin complex, which includes folic acid, methylcobalamin, biotin, calcium pantothenate, and vitamins B1, B2, B3, and B6. RBFIX-FE is primarily indicated for the management of iron deficiency anemia and nutritional deficiencies, particularly in patients with chronic kidney disease (CKD) who often face dietary restrictions. The combination works synergistically to enhance red blood cell production, maintain healthy hemoglobin levels, and lower blood homocysteine levels, thereby supporting cardiovascular and neurological health.

Brand names: RBFix FERBFIX-FE
Other names: vitamins + ferrous ascorbate

Beyond the preview

Go deeper on RBFIX-FE.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RBFIX-FE.